Literature DB >> 23754290

Staphylococcal superantigen-like protein 10 (SSL10) inhibits blood coagulation by binding to prothrombin and factor Xa via their γ-carboxyglutamic acid (Gla) domain.

Saotomo Itoh1, Ryosuke Yokoyama, Go Kamoshida, Toshinobu Fujiwara, Hiromi Okada, Takemasa Takii, Tsutomu Tsuji, Satoshi Fujii, Hideki Hashizume, Kikuo Onozaki.   

Abstract

The staphylococcal superantigen-like protein (SSL) family is composed of 14 exoproteins sharing structural similarity with superantigens but no superantigenic activity. Target proteins of four SSLs have been identified to be involved in host immune responses. However, the counterparts of other SSLs have been functionally uncharacterized. In this study, we have identified porcine plasma prothrombin as SSL10-binding protein by affinity purification using SSL10-conjugated Sepharose. The resin recovered the prodomain of prothrombin (fragment 1 + 2) as well as factor Xa in pull-down analysis. The equilibrium dissociation constant between SSL10 and prothrombin was 1.36 × 10(-7) M in surface plasmon resonance analysis. On the other hand, the resin failed to recover γ-carboxyglutamic acid (Gla) domain-less coagulation factors and prothrombin from warfarin-treated mice, suggesting that the Gla domain of the coagulation factors is essential for the interaction. SSL10 prolonged plasma clotting induced by the addition of Ca(2+) and factor Xa. SSL10 did not affect the protease activity of thrombin but inhibited the generation of thrombin activity in recalcified plasma. S. aureus produces coagulase that non-enzymatically activates prothrombin. SSL10 attenuated clotting induced by coagulase, but the inhibitory effect was weaker than that on physiological clotting, and SSL10 did not inhibit protease activity of staphylothrombin, the complex of prothrombin with coagulase. These results indicate that SSL10 inhibits blood coagulation by interfering with activation of coagulation cascade via binding to the Gla domain of coagulation factor but not by directly inhibiting thrombin activity. This is the first finding that the bacterial protein inhibits blood coagulation via targeting the Gla domain of coagulation factors.

Entities:  

Keywords:  Bacterial Toxins; Blood Coagulation Factors; Coagulation Factors; Prothrombin; Staphylococcal Superantigen-like Protein; Staphylococcus aureus

Mesh:

Substances:

Year:  2013        PMID: 23754290      PMCID: PMC3724617          DOI: 10.1074/jbc.M113.451419

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Structural relationships and cellular tropism of staphylococcal superantigen-like proteins.

Authors:  Ali M Al-Shangiti; Claire E Naylor; Sean P Nair; David C Briggs; Brian Henderson; Benjamin M Chain
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

2.  On the mechanism of fibrin-specific plasminogen activation by staphylokinase.

Authors:  H R Lijnen; B Van Hoef; F De Cock; K Okada; S Ueshima; O Matsuo; D Collen
Journal:  J Biol Chem       Date:  1991-06-25       Impact factor: 5.157

3.  The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria.

Authors:  Ries Langley; Bruce Wines; Natasha Willoughby; Indira Basu; Thomas Proft; John D Fraser
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Characterization of a proteolytically modified form of human prothorombin.

Authors:  C Dode; M J Rabiet; O Bertrand; D Labie; J Elion
Journal:  Biochem Biophys Res Commun       Date:  1980-05-30       Impact factor: 3.575

6.  Genome diversification in Staphylococcus aureus: Molecular evolution of a highly variable chromosomal region encoding the Staphylococcal exotoxin-like family of proteins.

Authors:  J Ross Fitzgerald; Sean D Reid; Eeva Ruotsalainen; Timothy J Tripp; MengYao Liu; Robert Cole; Pentti Kuusela; Patrick M Schlievert; Asko Järvinen; James M Musser
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

7.  Evasion of Toll-like receptor 2 activation by staphylococcal superantigen-like protein 3.

Authors:  B W Bardoel; R Vos; T Bouman; P C Aerts; J Bestebroer; E G Huizinga; T H C Brondijk; J A G van Strijp; C J C de Haas
Journal:  J Mol Med (Berl)       Date:  2012-06-20       Impact factor: 4.599

8.  Identification of a novel gene cluster encoding staphylococcal exotoxin-like proteins: characterization of the prototypic gene and its protein product, SET1.

Authors:  R J Williams; J M Ward; B Henderson; S Poole; B P O'Hara; M Wilson; S P Nair
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

9.  Enzymatic properties of staphylothrombin, an active molecular complex formed between staphylocoagulase and human prothrombin.

Authors:  S Kawabata; T Morita; S Iwanaga; H Igarashi
Journal:  J Biochem       Date:  1985-12       Impact factor: 3.387

10.  Chemotaxis inhibitory protein of Staphylococcus aureus binds specifically to the C5a and formylated peptide receptor.

Authors:  Bent Postma; Miriam J Poppelier; Joost C van Galen; Eric R Prossnitz; Jos A G van Strijp; Carla J C de Haas; Kok P M van Kessel
Journal:  J Immunol       Date:  2004-06-01       Impact factor: 5.422

View more
  11 in total

1.  Structural basis for inhibition of TLR2 by staphylococcal superantigen-like protein 3 (SSL3).

Authors:  Kirsten J Koymans; Louris J Feitsma; T Harma C Brondijk; Piet C Aerts; Eddie Lukkien; Philip Lössl; Kok P M van Kessel; Carla J C de Haas; Jos A G van Strijp; Eric G Huizinga
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-17       Impact factor: 11.205

Review 2.  Staphylococcal manipulation of host immune responses.

Authors:  Vilasack Thammavongsa; Hwan Keun Kim; Dominique Missiakas; Olaf Schneewind
Journal:  Nat Rev Microbiol       Date:  2015-09       Impact factor: 60.633

3.  Prothrombin is a binding partner of the human receptor of advanced glycation end products.

Authors:  Genny Degani; Alessandra Altomare; Stefania Digiovanni; Beatrice Arosio; Guenter Fritz; Angela Raucci; Giancarlo Aldini; Laura Popolo
Journal:  J Biol Chem       Date:  2020-07-14       Impact factor: 5.157

Review 4.  Pathogenesis of Staphylococcus aureus Bloodstream Infections.

Authors:  Lena Thomer; Olaf Schneewind; Dominique Missiakas
Journal:  Annu Rev Pathol       Date:  2016-02-25       Impact factor: 23.472

5.  Cloning, expression, crystallization and preliminary X-ray diffraction studies of staphylococcal superantigen-like protein 1 (SSL1).

Authors:  Debabrata Dutta; Anirudha Dutta; Atanu Bhattacharjee; Amit Basak; Amit Kumar Das
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2014-04-15       Impact factor: 1.056

Review 6.  Evasion and interactions of the humoral innate immune response in pathogen invasion, autoimmune disease, and cancer.

Authors:  Trisha A Rettig; Julie N Harbin; Adelaide Harrington; Leonie Dohmen; Sherry D Fleming
Journal:  Clin Immunol       Date:  2015-07-02       Impact factor: 3.969

7.  A Diagnostic Serum Antibody Test for Patients With Staphylococcus aureus Osteomyelitis.

Authors:  Kohei Nishitani; Christopher A Beck; Alexander F Rosenberg; Stephen L Kates; Edward M Schwarz; John L Daiss
Journal:  Clin Orthop Relat Res       Date:  2015-05-27       Impact factor: 4.176

Review 8.  Interaction of host and Staphylococcus aureus protease-system regulates virulence and pathogenicity.

Authors:  Vigyasa Singh; Ujjal Jyoti Phukan
Journal:  Med Microbiol Immunol       Date:  2018-11-27       Impact factor: 3.402

9.  Severe Acquired Coagulopathy During Fulminant Staphylococcus aureus Sepsis Most Likely Caused by S. aureus Exotoxins (SSLs).

Authors:  Lonneke Draaijers; Robert-Jan Hassing; Menno Kooistra; Kok van Kessel; Marcel Hovens
Journal:  Eur J Case Rep Intern Med       Date:  2018-12-27

Review 10.  Immunohaemostasis: a new view on haemostasis during sepsis.

Authors:  Xavier Delabranche; Julie Helms; Ferhat Meziani
Journal:  Ann Intensive Care       Date:  2017-12-02       Impact factor: 6.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.